Gallium-68 DOTATATE

Drug Profile

Gallium-68 DOTATATE

Alternative Names: 68Ga-DOTA-TATE; 68Ga-DOTA-tyr3-Octreotate; DOTATATE-Ga68; GA-68 DOTATATE; GalioMedix; NETSPOT; Somakit-TATE

Latest Information Update: 30 Jan 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Advanced Accelerator Applications
  • Developer Advanced Accelerator Applications; Assistance Publique - Hopitaux de Marseille; Centre de recherche du Centre hospitalier universitaire de Sherbrooke; Radio-Isotope Therapy of America Foundation; RadioMedix
  • Class Imaging agents; Organometallic compounds; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters; Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroendocrine tumours
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Neuroendocrine tumours

Most Recent Events

  • 01 Feb 2018 Advanced Accelerator Applications has been acquired by Novartis
  • 03 Aug 2016 Launched for Neuroendocrine tumours (Diagnosis) in USA (IV)
  • 02 Jun 2016 Registered for Neuroendocrine tumours (Diagnosis) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top